Landscape of Nuclear Medicine in China and Its Progress on Theranostics.

Autor:	Yang W; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China., Kang F; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China., Chen Y; Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, China., Zhu Z; Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China., Wang F; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China., Qin C; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; and., Du J; China Isotope and Radiation Corporation, Beijing, China., Lan X; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; and hzslxl@163.com 13909245902@163.com., Wang J; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China; hzslxl@163.com 13909245902@163.com.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 May 06; Vol. 65 (Suppl 1), pp. 29S-37S. Date of Electronic Publication: 2024 May 06.
DOI:	10.2967/jnumed.123.266968
Abstrakt:	Nuclear medicine in China started in 1956 and, with the rapid development of the economy and continuous breakthroughs in precision medicine, has made significant progress in recent years. Almost 13,000 staff members in nearly 1,200 hospitals serve more than 3.9 million patients each year. Over the past decade, the radiopharmaceutical industry has developed rapidly, with the initial formation of a complete industrial chain of production of various radiopharmaceuticals for both clinical use and basic research. Advanced equipment such as PET/CT scanners is being manufactured domestically and even installed abroad. Recently, research into screening and synthesizing new target probes and their translation into the clinic has gained more attention, with various new tracers with potential clinical value being thoroughly studied. Simultaneously, 68 Ga- and 177 Lu-labeled tumor-targeted probes and others have been implemented for theranostics in an increasing number of hospitals and would be helped by approval from the National Medical Products Administration. Over the next 10-20 y, with the launch of the Mid- and Long-Term Development Plan for Medical Isotopes (2021-2035) by the Chinese government, there is great potential for nuclear medicine in China. With the rise in independent innovation in manufacturing, the shortage of radiopharmaceuticals will be effectively curtailed. We anticipate that the scale of nuclear medicine will at least double by 2035, covering all high-grade hospitals and leading to the aim of "one county, one department" in China. (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu